Incyte Corporation (INCY)
Healthcare · Biotechnology · Data as of 2026-09-01
Bottom line
INCY is trading at a discount to its history, in the middle of its recent price range, and recent volume shows no clear direction. The picture is mixed, so it may be worth watching rather than acting on. Past patterns are not a guarantee of future results.
Valuation — Growth looks cheaper than its price (Green)
For a fast-growing company like INCY (revenue is growing about 21% a year), we weigh next year's expected P/E of 33× against the 127% earnings growth analysts expect (a forward PEG of 0.26, 13 estimates). Historically, paying less than 1× growth has been the cheaper side. Its current multiple sits around the 11th percentile of its own last five years — toward the low end of its own range.
Price zones — In the middle of its recent range (Yellow)
At $125.01, the stock sits between its recent support and resistance levels. Over the past year INCY has traded between $81.09 and $132.60; its historical support zone sits near $119.54 and resistance near $132.60. It is above both its 50- and 200-day averages, which has historically signalled an uptrend.
52-week range $81.09–$132.60 · 50-day average $119.54 · 200-day average $104.37
Money flow — No clear direction (Yellow)
Buying and selling volume in INCY have been fairly balanced recently, with no strong accumulation or distribution pattern. Volume on up days has been about 1.0× volume on down days over the last 30 sessions.
About the company
Incyte Corporation is a biopharmaceutical firm engaged in the research, development, and global marketing of its own innovative therapies. Its current product offerings include JAKAFI, prescribed for myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that targets oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor utilized for chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. Beyond its marketed drugs, Incyte's pipeline features several promising candidates.
一句话结论
INCY 相对自身历史处于折价水平，处于近期价格区间的中部，近期成交量没有明确方向。整体情况好坏参半，也许更适合先观察，而不是急于行动。过去的形态并不能保证未来的结果。
估值 — 增长相对其价格显得便宜
对 INCY 这样的高增长公司（营收年增长约 21%），我们把它明年的预期市盈率 33× 与分析师预计的 127% 盈利增速放在一起看（前瞻 PEG 为 0.26，来自 13 份预测）。从历史来看，付出低于 1 倍增长的价格属于较便宜的一侧。它当前的估值倍数大约位于自身过去五年分布的第 11 百分位——处于自身区间的偏低位置。
价格区间 — 处于近期区间的中部
目前价格为 $125.01，位于其近期的支撑位与阻力位之间。过去一年 INCY 的价格在 $81.09 到 $132.60 之间波动；其历史支撑区在 $119.54 附近，阻力区在 $132.60 附近。它同时位于 50 日和 200 日均线上方，这在历史上通常对应上升趋势。
资金流向 — 方向不明确
INCY 近期的买卖成交量大致均衡，没有明显的吸筹或派发形态。过去 30 个交易日，上涨日的成交量约为下跌日的 1.0×。
UnderTheLight 用直白的语言解释股票——估值、价格区间与资金流向。它只描述数据，不构成任何投资建议。
UnderTheLight explains stocks in plain English — valuation, price zones and money flow as traffic lights, recomputed nightly. It describes data; it is not investment advice and never recommends a trade.